Pulse Biosciences, Inc. (PLSE) Announces CE Mark Approval for CellFX System
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Pulse Biosciences Announces CE Mark Approval for CellFX® System
January 25, 2021 8:00 AM EST- CellFX System Delivers Nano-Pulse Stimulation Technology to Clear Hard-to-Treat Benign Skin Lesions
- First CellFX System Shipment Scheduled to Commence Controlled Launch Program with Clinical Aesthetic Experts in the European Union
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (Pulse Biosciences or the Company), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced Conformité Européene (CE) mark approval for the CellFX® System. The CE mark confirms that the CellFX System meets the requirements of the European Medical Devices Directive. This allows the Company to... More
